Recent investigations into the relationship between cancer and cellular metabolism have revealed the strong dependency of different cancers on a diverse array of metabolic pathways. Therefore, identification of the mechanisms by which these metabolic pathways become deregulated in the first place en route to, or as a result of, the development of cancer has emerged as a major area of therapeutic and biological interest.
Recent investigations into the relationship between cancer and cellular metabolism have revealed the strong dependency of different cancers on a diverse array of metabolic pathways. Therefore, identification of the mechanisms by which these metabolic pathways become deregulated in the first place en route to, or as a result of, the development of cancer has emerged as a major area of therapeutic and biological interest.
Deregulation of metabolic pathways can occur through multiple mechanisms, including alterations in the cellular landscape brought about by mutations in genes encoding metabolic enzymes (such as those encoding isocitrate dehydrogenase (IDH1 and IDH2) and succinate dehydrogenase (SDHB, SDHC, and SDHD)) [1] [2] [3] [4] . Mutations in IDH1 and IDH2, which are initiating events in high-grade gliomas and frequently occur in individuals with acute myeloid leukemia (AML), interfere with normal IDH1 and IDH2 function to produce the prooncogenic metabolite (R)-2-hydroxyglutarate, which functions as an epigenetic modulator [5] [6] [7] [8] . Deregulation of metabolic pathways can also occur through aberrant expression of transcription factors, such as the transcription factor MYC. Transcriptional changes resulting from aberrantly activated MYC lead to increased glucose uptake and glycolysis in cancer cells and the stimulation of glutaminolysis, serine-glycine metabolism and lipid biosynthesis 9 . Although MYC and other transcription factors are typically considered pharmacologically challenging targets, the diverse metabolic alterations induced by these transcription factors may constitute another source of unique cancer dependencies and provide multiple downstream opportunities for therapeutic intervention. It is thus necessary not only to identify the metabolic changes which occur with cancer development but to link these programs to initiating events and oncogenic drivers; the latter will enable identification of patient populations that may benefit from specific metabolic interventions.
Transcriptional modulators are deregulated in AML either by translocation of the encoding gene (for example, the fusions KMT2A-MLLT3, RUNX1-RUNX1T1 or PML-RARA) or by aberrant expression (for example, EVI1) 10, 11 . Abnormal expression of this transcription factor through chromosome 3q26 rearrangements (for example, t(3;3)(q21;q26) or inv3(q21;q26)) promotes the development or progression of high-risk AML, for which current treatment a r t i c l e s 3 0 2 VOLUME 23 | NUMBER 3 | MARCH 2017 nature medicine regimens remain inadequate [12] [13] [14] [15] . Here we integrated genomic and metabolic screening to identify a new druggable metabolic dependency for EVI1-positive AML in mouse and human cells, including cell lines and primary patient samples.
RESULTS

EVI1 modulates metabolism in a mouse cell model of AML
To characterize the transcriptional consequences of EVI1 overexpression in individuals with AML, we generated an Evi1-dependent gene signature from mouse bone marrow lineage low (Lin low ) cells that were infected with a retroviral construct encoding Evi1 (GSE34729) 16 . We then used this signature to conduct an open-ended enrichment analysis of 4,725 curated gene sets from the c2 collection of gene sets, which was assembled from various sources such as online pathway databases, publications in the PubMed database, and knowledge of domain experts available from the Molecular Signatures Database (MSigDB) (Fig. 1a) . We confirmed findings by other investigators that gene sets related to cell proliferation and differentiation were enriched in genes whose expression is suppressed by enforced Evi1 overexpression [16] [17] [18] . Multiple cell-metabolism-related gene sets were also markedly enriched in an unbiased search of the complete c2 collection. Evi1 overexpression resulted in the modulation of genes whose products are associated with cellular-energy-related pathways, including glycolysis, the tricarboxylic acid (TCA) cycle and oxidative phosphorylation, purine and pyrimidine synthesis, and the metabolism of various amino acids (Fig. 1b) . By using an unbiased metabolomic profiling approach, we established that of 292 small metabolites detected by mass spectrometry, steady-state levels of 82 were significantly (−log 10 (P value) ≥ 1) changed by Evi1 expression (Supplementary Fig. 1 ). The most highly enriched metabolic pathways were related to purine and pyrimidine metabolism, amino acid metabolism (alanine, aspartate, glutamate, arginine and proline), the pentose phosphate pathway and glycolysis (Fig. 1c) .
To assess whether upregulation of EVI1 in cell lines derived from leukemic cells from human individuals with AML (hereafter referred to as human AML cell lines) might promote oncogenic dependency on metabolic enzymes, we performed an shRNA screen against 67 genes that encode enzymes involved in glycolysis, the pentose phosphate pathway, the TCA cycle and related metabolic pathways in the AML cell lines TF-1 and UCSD-AML1, both of which express EVI1. These cells were infected with the shRNA library and expanded until day 36, at which point genomic DNA was harvested, and hairpin representation was assessed by sequencing and compared to the representation of the input genomic DNA at day 0. We identified hairpin sequences that were depleted (hairpins that targeted expression of genes involved in promoting leukemia) or enriched (hairpins that targeted expression of genes involved in suppressing leukemia) at 36 d relative to the same sequences from input genomic DNA. These experiments identified an overlap of nine genes whose expression was depleted and six genes whose expression was enriched in both cell lines, which tested with at least two hairpins ( Fig. 1d and Supplementary Table 1 ). As expected, three tumor suppressor genes that were used as positive controls-phosphatase and tensin homolog (PTEN), tumor protein p53 (TP53) and RB transcriptional co-repressor 1 (RB1)-scored among the top enriched hits. Three genes of interest-Ckmt1, citrate synthase (Cs) and Sdha-were both upregulated by genomic profiling in Evi1-transduced mouse cells and depleted by multiple shRNAs in the TF-1 and UCSD-AML1 human AML cell lines (Fig. 1e) . We then infected TF-1 AML cells with multiple hairpins whose expression markedly reduced CKMT1, SDHA and CS protein levels (Fig. 1f) . Although expression of all of the hairpins substantially decreased cell growth over a 12-d time course, depletion of CKMT1 expression caused the most pronounced growth inhibition (Fig. 1f) .
CKMT1 is a target in EVI1-positive leukemia
To address the potential relationship between EVI1 expression and cell dependence on CKMT1, we expanded our investigation to a larger panel of human AML cell lines that had or did not have increased EVI1 expression. All four EVI1-expressing AML cell lines showed increased CKMT1 protein expression and activity (Fig. 2a,b) . The viability of these four cell lines was more strongly decreased, as compared to the viability of all of the other lines tested, in response to a treatment with cyclocreatine, an analog of the CKMT1 substrate creatine and an inhibitor of the creatine biosynthesis pathway (Fig. 2c) . Furthermore, three AML cell lines with increased EVI1 expression-UT-7, TF-1 and UCSD-AML1-showed enhanced sensitivity to a reduction in CKMT1 expression mediated by doxycycline-inducible expression of shRNAs than the other cell lines tested (Fig. 2d) . The human Kasumi-3 cell line was not tested in this experiment owing to its poor transduction efficiency. Similar growth defects were observed with non-inducible CKMT1-targeting shRNAs ( Supplementary Fig. 2a,b) . These AML cell lines are grown Colored boxes indicate an enrichment odds ratio (OR) >3 (black), between 2 and 3 (dark gray), between 1 and 2 (light gray) and <1 (white). (c) Pathway analysis integrating enrichment and pathway topology analyses (MetaboAnalyst) of the steady-state metabolite profile from control versus Evi1-overexpressing Lin Low mouse bone marrow cells. The top 15 out of a total of 45 metabolic pathways are represented based on FDR ≤ 0.1 and P ≤ 0.05. "Hits" represents the number of metabolites that scored in the steady-state profile, and "Total" represents the number of metabolites present in the given metabolic pathway. Metabolic pathways with a −log 10 (FDR) ≥ 1.5 are depicted in red, 1 ≤ −log 10 (FDR) < 1.5 are in orange, and −log 10 (FDR) < 1 are in beige. (d) Scatter plot of hits that were significantly (−log 10 (FDR) ≥ 1) depleted (in blue) or enriched (in red) from an shRNA library targeting 67 metabolism-related genes in the human TF-1 (top) and UCSD-AML1 (bottom) cell lines. Hits that did not score are depicted in black. Data are presented as volcano plots of −log 10 (FDR) versus the RIGER enrichment score for each gene. (e) Heat map of genes encoding metabolism-related factors that are differentially expressed by genomic profiling in GSE34729 after Evi1 overexpression in Lin Low bone marrow cells (left) and heat map of genes that were either depleted (in blue) or enriched (in red) in the shRNA screen in TF-1 and UCSD-AML1 cells (right). Genes that were both upregulated after Evi1 overexpression and depleted in the shRNA screen are in blue. CT, control transduced with an empty vector. Each column for each condition represents a technical replicate (n = 3 per condition). (f) Left, growth of TF-1 cells that were infected with retroviruses encoding hairpins directed against CKMT1, SDHA or CS (n = 7 replicates per group). Right, immunoblot confirming shRNA target knockdown. shCT, control shRNA. Error bars represent mean ± s.d. *P ≤ 0.05 and # P ≤ 0.05, as calculated on the latest time point using a nonparametric Kruskall-Wallis test and Dunn's multiple-comparisons test. Data are representative of two independent experiments. 
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in granulocyte-macrophage colony-stimulating factor (GM-CSF), and withdrawal of GM-CSF affected neither CKMT1 expression nor sensitivity of EVI1-expressing cells to treatment with cyclocreatine ( Supplementary Fig. 2c,d) . Conversely, GM-CSF supplementation did not promote CKMT1 expression in the two AML cell lines that represented EVI1-null, CKMT1-null cells, HL-60 and U937 (Supplementary Fig. 2e ).
Finally, we assayed EVI1 expression by flow cytometry in a panel of 68 randomly selected primary specimens from patients with AML ( Fig. 2e and Supplementary Table 2) . Samples with at least 5 × 10 6 blast cells were subsequently analyzed by flow cytometry and immunoblot analysis. The four leukemia samples with the highest levels of EVI1 expression showed higher CKMT1 protein levels and enhanced sensitivity to cyclocreatine treatment than the leukemia samples with low EVI1 expression (Fig. 2e-g ). Taken together, these studies indicate that elevated CKMT1 expression and biochemical dependence on this metabolic pathway are correlated with high levels of EVI1 expression in both human AML cell lines and primary patient specimens.
EVI1 promotes CKMT1 expression through RUNX1 repression To clarify the mechanism by which EVI1 regulates cellular CKMT1 expression, we first infected mouse Lin low c-kit + bone marrow cells with either an empty GCDN vector or with a construct encoding Evi1. Consistent with our analysis of human AMLs, enforced Evi1 expression increased Ckmt1 protein and Ckmt1 mRNA levels (Fig. 3a,b) . Moreover, doxycycline-induced expression of three independent shRNA molecules targeting EVI1 reduced CKMT1 expression in TF-1 and UCSD-AML1 cells (Fig. 3c) . We then used a luciferase reporter system in which the CKMT1 gene promoter was cloned upstream of a luciferase cassette (CKMT1-Luc) to assess levels of CKMT1 transactivation by bioluminescence (Fig. 3d) . Co-expression of EVI1 and the CKMT1-Luc reporter in HEK293E cells activated CKMT1 transcription. Deletion of a promoter region between −1,169 and −943 bp upstream of the transcriptional start site (referred to as −1,169/−943 CKMT1 promoter) increased basal CKMT1 transactivation to a level similar to that observed after EVI1 overexpression (Fig. 3d) . This effect was recapitulated by deletion of a RUNX1 consensus binding motif ACCACA (∆ACCACA) from the −1169/−943 CKMT1 promoter sequence (Fig. 3e) , suggesting that RUNX1 might repress CKMT1 expression through direct binding to the CKMT1 promoter. Consistent with this idea, RUNX1 overexpression impeded the capacity of EVI1 to transactivate CKMT1 (Fig. 3f) . EVI1 knockdown promoted both an increase in RUNX1 and a decrease in CKMT1 expression. Furthermore, RUNX1-directed shRNAs, which abrogated the upregulation of RUNX1 expression, prevented a decrease of CKMT1 expression after EVI1 knockdown (Fig. 3g) .
We then used a chromatin immunoprecipitation (ChIP)-qPCR approach to dissect the sequential events involved in EVI1-induced CKMT1 upregulation and the possible role of RUNX1 as an intermediate in this process ( Fig. 3h-l) . Multiple red peaks, which corresponded to EVI1-binding regions, appeared on gene tracks for both mouse Runx1 and human RUNX1 in two ChIP-sequencing experiments 19, 20 (Fig. 3h) . After immunoprecipitation of Evi1 from Evi1-overexpressing mouse primary bone marrow cells and amplification of the Runx1 promoter sequence by qPCR, we found a significant increase in Evi1 binding at the Runx1 promoter, which was accompanied by an increased amount of trimethylated Lys27 on histone H3 (H3K27Me3), a histone mark associated with repressed gene expression, at the same promoter region (Fig. 3i) . This was associated with a decrease in RUNX1 expression at the mRNA and protein levels ( Supplementary Fig. 3a,b) . At basal conditions, Runx1 is bound to Ckmt1 promoter in normal bone marrow cells. Evi1 overexpression, however, decreased Runx1 binding to the Ckmt1 promoter, as well as the amount of associated H3K27me3, and increased the binding signal of acetylated H3K27 (H3K27Ac), a transcriptional activation histone mark (Fig. 3j) . This was associated with increased Ckmt1 expression at the mRNA and protein levels ( Supplementary  Fig. 3a,b) . In contrast, EVI1 knockdown in UCSD-AML1 cells enhanced RUNX1 expression and binding at the CKMT1 promoter ( Fig. 3k and Supplementary Fig. 3c,d ). EVI1 knockdown also resulted in an increased amount of bound H3K27Me3 and a reduced amount of bound H3K27Ac at the CKMT1 promoter, and it was associated with decreased expression of CKMT1 ( Fig. 3k and Supplementary  Fig. 3a-d) . In contrast, concomitant EVI1 and RUNX1 knockdown decreased the levels of the repressive H3K27Me3 histone mark at the CKMT1 promoter (Fig. 3l) . Taken together, these results show that EVI1 represses RUNX1 expression by directly binding to the RUNX1 promoter. This, in turn, eliminates repressive RUNX1 binding at the CKMT1 promoter and thereby promotes CKMT1 expression. Moreover, we also observed that RUNX1-directed shRNAs attenuated the reduced disease burden caused by EVI1 depletion by 17-fold, based on the average bioluminescence observed across the two hairpins (Fig. 3m) . Finally, we explored the relationship between EVI1 and RUNX1 expression with CKMT1 mRNA levels in two transcriptional data sets of individuals with AML (GSE14468 and GSE10358). We divided these cohorts into four subgroups: EVI1 high RUNX1 low , EVI1 high RUNX1 high , EVI1 low RUNX1 low and EVI1 low RUNX1 high . Consistent with our mechanistic analysis, samples from individuals with AML associated with high CKMT1 mRNA levels were significantly more represented within the EVI1 high RUNX1 low subgroup than in the three other subgroups (Fig. 3n) .
Creatine kinase drives mitochondrial function and ATP production CKMT1 promotes the metabolism of arginine to creatinine. To determine the effect of CKMT1 suppression on this pathway, we measured the metabolic flux of stable-isotope labeled l-[ 13 C 6 ]arginine through creatine synthesis, the ornithine-spermine and ornithineurea cycle, and the glutamate pathway using mass spectrometry (Fig. 4a) . As expected, both CKMT1 knockdown and cyclocreatine treatment in UCSD-AML1 and TF-1 cells diminished incorporation of l-[ 13 C 6 ]arginine into creatinine. Creatinine is the end metabolite product of the creatine synthesis pathway and is spontaneously synthesized from phosphocreatine ( Fig. 4a-c and Supplementary  Fig. 4a ). We also observed a marked decrease in l-[ 13 C 6 ]arginine 19 and Glass et al. 20 . (i-l) ChIP-qPCR analyses for Lin Low c-Kit + mouse bone marrow cells overexpressing a vector encoding Evi1 (i,j), human UCSD-AML1 cells expressing shControl (shCT) or one of three EVI1-directed shRNAs (k) or human UCSD-AML1 cells expressing combinations of EVI1-and RUNX1-directed shRNAs (l) following ChIP with the indicated antibodies (ChIP Ab) and qPCR on the indicated promoter regions. Results are represented as fold enrichment relative to input. In d-l, data are mean ± s.d. of three technical replicates. *P ≤ 0.05 by Welch's t-test. Each experiment in a-l was performed at least two independent times. (m) Disease burden, as assessed by weekly bioluminescence measurements, in mice that were injected with a luciferase-expressing human TF-1-Luc AML cell line cells overexpressing colony-stimulating factor 2 (CSF2) (for efficient engraftment) and a combination of two EVI1-and one RUNX1-directed shRNAs. Data are represented as mean ± s.e.m. of five mice per cohort. *P ≤ 0.05 by nonparametric Mann-Whitney U test (calculated on the 7-week time point). (n) Bar graph showing the number of primary samples from patients with AML, with EVI1 high RUNX1 low , EVI1 high RUNX1 high , EVI1 low RUNX1 low or EVI1 low RUNX1 high expression and showing high versus low levels of CKMT1 expression (absolute cut-off of a z-score ≥ 0.58 is considered to be a high level of expression, and a z-score ≤ −0.58 is considered to be a low level of expression) in two cohorts: GSE14468 (left) and GSE10358 (right). P values were calculated using Fisher's exact test.
incorporation into the precursor metabolite of the creatine synthesis pathway, guanidinoacetate, suggesting an inhibitory feedback loop of end metabolite products on the guanidinoacetate-producing enzyme glycine amidinotransferase (GATM). Of note, cyclocreatine treatment had a broader effect than shRNA-mediated CKMT1 depletion on arginine metabolism because it also impaired production of glutamate, α-ketoglutarate, and l-arginino-succinate (Fig. 4c) . Co-treatment of cells with exogenous phosphocreatine activated production of synthesis pathway alone, without affecting production of glutamate, α-ketoglutarate and l-arginino-succinate ( Fig. 4c and Supplementary  Fig. 4b) . Activation of the arginine-creatine pathway by phosphocreatine prevented the loss of viability of human EVI1-positive AML cells induced by cyclocreatine treatment or by CKMT1-directed shRNAs, and it also maintained the serial replating activity of Evi1-overexpressing bone marrow cells (Fig. 4d-f) .
We next used a metabolism-profiling approach to characterize the effect of creatine kinase pathway alteration on global cell metabolism. Steady-state levels of 48 metabolites highly enriched in pathways related to purine metabolism, amino acid metabolism (glycine, serine, threonine, arginine and proline) and energy metabolism (TCA cycle and glycolysis) were significantly changed by CKMT1 suppression in TF-1 and UCSD-AML1 cells (Fig. 4g,h ). This analysis revealed a significant (P ≤ 0.05) decrease in intracellular ATP levels that was accompanied by an increase in ADP and AMP levels (Fig. 4g) . This increase in the ADP/ATP ratio induced by creatine kinase pathway inhibition was only observed in the four AML cell lines expressing a high level of CKMT1 (TF-1, UT-7, UCSD-AML1 and Kasumi-3) but not in those expressing a low level of CKMT1 (Fig. 4i) . Finally, activation of the creatine pathway by phosphocreatine rescued the cyclocreatine-induced decrease in intracellular ATP level, suggesting that the creatine pathway may regulate ATP production in CKMT1-expressing cells (Fig. 4j) .
To investigate this hypothesis, we evaluated the effect of creatine pathway inhibition on the respiration capacity of the mitochondria, the main organelles involved in ATP production. Measurement of the mitochondrial oxygen consumption rate (OCR) reflects the capacity to produce ATP. Cyclocreatine treatment decreased basal mitochondrial respiration capacity in both TF-1 and UCSD-AML1 cells, as well as the maximal mitochondrial respiration capacity visualized after FCCP supplementation (which uncouples oxygen consumption from ATP production) in UCSD-AML1 cells (Fig. 4k) . Co-treatment with phosphocreatine counteracted the effect of cyclocreatine and restored normal mitochondrial respiration capacity, suggesting that an active creatine pathway is required for promoting mitochondrial activity.
Finally, we overexpressed a wild-type (WT) or a metabolically inactive mutant form of CKMT1 (CKMT1 C316G ) (ref. 21 ) in two AML cell lines, NB-4 and U937, that do not express endogenous CKMT1 (Supplementary Fig. 5a ). WT but not CKMT1 C316G conferred cyclocreatine sensitivity to these two cell types (Supplementary Fig. 5b) , and cyclocreatine treatment significantly reduced ATP production and basal mitochondrial respiration in cells expressing WT CKMT1 (Supplementary Fig. 5c,d) . Taken together, these data demonstrate that expression of CKMT1 renders mitochondria dependent on creatine pathway activity for ATP production.
Blockade of creatine kinase activity diminishes the viability of EVI1-expressing cells To determine the transcriptional consequences of creatine kinase pathway inhibition in EVI1-expressing cells, we used RNA sequencing (RNA-seq) to profile three EVI1-expressing cell lines (TF-1, UT-7 and UCSD-AML1) before and after treatment with cyclocreatine for 24 h. We identified 54 and 53 genes whose expression was substantially (1.5-fold) upregulated and downregulated, respectively, after cyclocreatine treatment, relative to their expression after control treatment (Fig. 5a) . We then conducted an open-ended enrichment analysis using a relaxed cyclocreatine signature (defined based on the cutoff signal-to-noise ratio (SNR) permutation P ≤ 0.05, BenjaminiHochberg false discovery rate (FDR) ≤ 0.05 and absolute fold change for log 2 (fragments per kb of transcript per million mapped reads; FKPM) scores ≥ 0.5.) on the entire set of signatures from the c2 (MsigDB) and Differentiation Map (DMAP) collections of gene sets (Supplementary Tables 3 and 4) . Gene sets related to cell cycle, energy metabolism and cell stemness were enriched for genes whose expression was suppressed by cyclocreatine treatment, and gene sets related to cell differentiation were more enriched in genes whose downregulation was induced by treatment with pro-differentiating agents or cyclocreatine. Finally, gene sets associated with amino acid (k) Mitochondrial OCR of human UCSD-AML1 and TF-1 cells that were treated with 5 mM cyclocreatine (Ccr) in combination with 1 mM phosphocreatine (P-Cr) for 12 h before measurement under basal conditions, following sequential injections of the ATP synthase inhibitor oligomycin (1 µM), the uncoupling agent FCCP (1 µM) and the complex I and III inhibitors rotenone and antimycin A (1 µM each), respectively. Data are mean ± s.d. of four technical replicates. *P ≤ 0.05 by Mann-Whitney U test (relative to the control condition). Each experiment was performed at least two independent times, except in g,h in which two different EVI1-positive human cell lines that were transduced with two different CKMT1-directed shRNAs were profiled using metabolomics. metabolism were more enriched for genes that were upregulated by cyclocreatine treatment (Fig. 5b,c, and Supplementary Table 5) . At the intersection of the genes involved in the three functional groups enriched-cell cycle, cell stemness and cell differentiation-a leadingedge analysis isolated a core of ten genes that were significantly (P value < 0.05) downregulated by cyclocreatine treatment in the three lines profiled (Supplementary Fig. 6a) . We used real-time PCR to validate the transcriptional downregulation of MYC and CCND1 (which encodes cyclin D1) in all of the EVI1-positive cell lines after treatment with cyclocreatine ( Supplementary Fig. 6b ). Treatment with cyclocreatine or expression of CKMT1-directed shRNAs resulted in increased cell size and cell vacuolization (Fig. 5d-f) . This was accompanied by a G0/G1 cell cycle arrest in the UCSD-AML1 and Kasumi-3 cell lines, whereas TF-1 and UT-7 underwent apoptosis (Fig. 5g,h) . Finally, expression of CD117, which is a cell surface marker for immature cells, decreased in response to treatment with cyclocreatine or expression of CKMT1-directed shRNAs, and this was associated with inhibition of the serial replating activity of UCSD-AML1, TF-1 and UT-7 cells (Fig. 5i,j) . 22, 23 , which express a mutant form of Nras (Nras G12D ) induced by the activation of the Cre transgene under the control of the Mx1 promoter. We compared two types of mice with Nras G12D -dependent AML from this screen-Nras G12D + Evi1, which contains a clonal Evi1 integration and expresses high transcript levels of Evi1, and a control Nras G12D -expressing AML that does not express Evi1. Immunoblot analysis of these cell types revealed markedly increased levels of Evi1 and Ckmt1 in the Nras G12D + Evi1 AML (Fig. 6a) , and this leukemia was also more sensitive to inhibition by cyclocreatine treatment than bone marrow cells from WT or Nras G12D mice (Supplementary Fig. 7a ). To examine the oncogenic Evi1 dependency on Ckmt1 expression, we transduced bone marrow cells from Nras G12D and Nras G12D + Evi1 mice with a doxycycline-inducible nontargeting control (CT) or two Ckmt1-directed shRNAs. Successfully transduced cells, which were positive for the expression of the Venus fluorescent marker, were then sorted and injected into irradiated recipient mice. After disease onset was detected, mice were treated with doxycycline to induce shRNA expression in tandem with a red fluorescent protein (RFP) reporter cassette, and knockdown was confirmed by immunoblot analysis (Fig. 6b) . Recipient mice that were transplanted with bone marrow cells from Nras G12D mice after transduction with either control or Ckmt1-directed shRNAs, or Nras G12D + Evi1 AML cells expressing a nontargeting control shRNA (shControl) succumbed to aggressive AML with a median latency of ~20 d. By contrast, recipients of shCkmt1_2-or shCkmt1_3-transfected bone marrow cells from NRas G12D + Evi1 mice had attenuated disease and survived for ~40 d (Fig. 6c) . Splenomegaly and leukocytosis, which reflect the AML disease burden, were also markedly reduced in mice that were transplanted with the shCkmt1_2-or shCkmt1_3-expressing NRas G12D + Evi1 bone marrow cells, as compared to mice that were transplanted with shControl-expressing bone marrow cells (Fig. 6d) , and the splenic proportion of Gr-1 + Mac-1 + granulocytes was substantially less than that in shControl-expressing NRas G12D + Evi1 mice (Fig. 6e) . Although all of the Nras G12D + Evi1 mice showed a recurrent expansion within the Lin Low Sca-1 − c-Kit + CD16 + CD32 + CD34 + granulocyte-macrophage progenitor (GMP) compartment, as compared to that in WT mice, Nras G12D mice showed dominant growth of a less immature Lin Low Sca-1 − c-Kit + CD16 + CD32 + CD34 − population (representative examples in Fig. 6f) . In Nras G12D mice, Ckmt1 knockdown did not alter the growth of the leukemic population, as compared to that in mice with the shControl-expressing bone marrow cells. In recipients that were transplanted with the Nras G12D + Evi1 bone marrow cells, Ckmt1 knockdown suppressed the expansion of the RFP + Venus + leukemic population from 58% in shControl mice to 2% in the shCkmt1 group, thus reducing the overall growth advantage of the GMP fraction over the megakaryocyte-erythroid progenitor (MEP) and common myeloid progenitor (CMP) populations. To assess the effects of Ckmt1 deletion on normal hematopoiesis, CD45.2 bone marrow cells that expressed shCT were transplanted into lethally irradiated recipient mice with an equal number of CD45.1 competitor bone marrow cells that expressed the Ckmt1-directed shRNAs (Supplementary Fig. 7b ). We confirmed chimerism by evaluating the ratio of CD45.1 to CD45.2 cells in the bone marrow of recipient mice (Supplementary Fig. 7c, top panel) . Reducing Ckmt1 expression did not alter the repopulating potential of normal hematopoietic cells in competitive transplantation assays, suggesting no toxic effect of Ckmt1 targeting in normal bone marrow cells (Supplementary Fig. 7c, bottom panel) .
Finally, we investigated the effects of either expression of doxycycline-inducible CKMT1-directed shRNAs or cyclocreatine treatment on leukemia development in xenografts of luciferase-expressing EVI1 low U937-Luc and EVI1 high TF-1 CSF2 + -Luc human AML cell lines. Leukemia burden was monitored in recipient mice. Mice were then treated therapeutically with doxycycline or cyclocreatine after disease burden was detected at day 8 with U937 cells and at day 10 with TF-1 cells (Supplementary Fig. 7d,e) . Consistent with our in vivo analysis of primary cells from Nras-mutated mice with AML, pharmacologic or genetic inhibition of the CKMT1-dependent pathway blocked disease progression and prolonged the survival of mice that were injected with TF-1 cells but not with U937 cells (Fig. 6g,h) . Co-treatment with phosphocreatine significantly rescued the effects of cyclocreatine in mice that were injected with TF-1 cells but had no effect in the mice injected with U937 cells (Fig. 6i) .
DISCUSSION
Here we found that overexpression of the zinc-finger transcription factor EVI1 remodeled the metabolic landscape of immature hematopoietic cells, particularly by affecting cell-energy-related pathways, arginine metabolism and de novo synthesis of purines and pyrimidines. The broad transcriptional effects of EVI1 overexpression on these different metabolic pathways are reminiscent of a recent study that identified glutaminolysis as a critical pathway for T cell acute lymphoblastic leukemia progression in mouse models downstream of the hyperactivated, mutant form of the transcription factor NOTCH1 and as a key determinant of the response to anti-NOTCH1 therapies 24 .
Other results suggest that glycolysis is important for MLL-AF9-driven maintenance and progression of AML and that those leukemic cells are more sensitive to the inhibition of aerobic glycolysis than normal hematopoietic cells 25 . This supports the idea that the pro-leukemic effects of EVI1 expression in AML may be mediated, at least in SDAD1  ARF3  HNRNPU  HYAL3  TPP2  CHKA  BCOR  SIN3A  FYB  POLR2B  PTCD3  PTPRA  INSR  SMARCAD1  PCNA  SREBF1  DHX40  TFB2M  DHX33  PRPSAP2  NFYB  SFPQ  RAB40B  DARS2  AZIN1  C5orf24  ETNK1  AQR  ETF1  GLS  PARP4  AP4S1  ARHGEF6  FLYWCH2  IFT74  PSME4  CTR9  PLEKHA6  PIGX  HNRNPM  BAZ1A  SLC2A6  MAVS  DCLRE1A  LRRC58  RBM12  LOC101927621  NCAPD3  ABHD4  CFP  ANKZF1  ZNF345  DDX49   POLG  LRRC70  IFITM10  RAPGEFL1  PCBP2  UIMC1  AVEN  MSL1  RAD52  MRRF  LEMD2  RPL19  NACA  GGCX  MTG1  THUMPD1  CLK4  CRTC1  RPS11  MAN2C1  BUD13  PRRG2  DRD4  MRPL10  SNHG6  FAM132A  RPL22  DNHD1  APOBEC3D  AURKB  FBXL5  LSMEM1  RHOG  TUBB  DAK  NRDE2  PNN  AFG3L1P  DPP7  ZNF335  RPL37  AOC3  FBXO42  YWHAH  EPB41L4A-AS1  MZT2B  SNRNP48  RPS2  SUMO2  PGLS  C6orf48  RPL18A  GAS5 part, by perturbations of cell metabolism and that targeting these metabolic dependencies may be promising therapeutic avenues in EVI1-positive leukemias.
Our results indicate a higher dependency of EVI1-positive leukemias on the creatine kinase pathway than other subgroups of AML. Creatine is one of the end products of the arginine pathway, which is altered after EVI1 overexpression. In healthy cells, arginine can be produced by the ornithine-citrulline-arginine cycle. However, recent investigations identified that the majority of blasts from patients with AML are deficient in enzymes specialized in promoting this cycle and are, therefore, strongly reliant on extracellular arginine availability 26, 27 . These studies suggest that a constitutive blockade of the ornithine-citrulline-arginine cycle would preferentially redirect transported arginine through other arginine-dependent metabolic pathways, such as the creatine pathway. Notably, a Mycoplasmaderived enzyme, ADI-PEG 20, that degrades extracellular arginine and thus prevents intracellular import of arginine showed good in vitro anti-leukemic efficacy in samples from 19 of a cohort of 38 patients with primary AML 28 . From the entire cohort, only one sample harbored a translocation involving EVI1, and this sample was sensitive to treatment with ADI-PEG 20. This finding would be consistent with the dependency of EVI-positive AML on the creatine kinase pathway and suggests that EVI1-positive patients may also be good responders to a therapy targeting the import of arginine.
CKMT1 has two main functions in energy metabolism-it buffers the cellular ATP pool by maintaining cytosolic concentrations of phosphocreatine for high cellular energy demand to regenerate ATP, and it maintains an energy shuttle between sites of energy supply and sites of energy demand using the easily diffusible creatine 29 . Our results showed that CKMT1 directly affects mitochondrial respiration and ATP production. This is reminiscent of the role of hexokinases, another class of mitochondria-coupled enzymes that utilize ATP produced by mitochondria to catalyze conversion of glucose into glucose-6-phosphate, the first rate-limiting step of glycolysis 30 . In turn, the ADP formed from this reaction stimulates mitochondrial respiration 31, 32 . Similarly, the increase in the rate of creatinephosphocreatine interconversion subsequent to CKMT1 overexpression seems to regulate mitochondrial respiration and then influence mitochondrial ATP production. The expression of CKMT1 alone is sufficient to reprogram mitochondrial activity, suggesting that CKMT1 upregulation itself may be one of the main contributors to metabolic perturbations that are necessary for the pro-leukemic effects of EVI1 in patients with AML.
Although CKMT1 is ubiquitously expressed, several studies have shown that some cancer types (such as mesotheliomas, small-cell lung cancer and brain tumors) expressed higher creatine kinase protein levels, which predict higher sensitivity to cyclocreatine 33 . Moreover, high levels of CKMT1 expression are a marker of poor prognosis for patients with breast cancer 34 . We established that EVI1 promotes CKMT1 expression by direct repression of the transcription factor RUNX1. A transcriptomic analysis of 269 patients with AML revealed that those who harbor t (8;21) or t(11q23) alterations show a WT RUNX1 signature, whereas patients bearing del(7q)/7 − or inv3/t(3;3), which are responsible for EVI1 overexpression, express a mutated-RUNX1-derived gene expression signature 35 . This corroborates our observation that CKMT1, whose expression is repressed by RUNX1, is predominantly upregulated in the EVI1-overexpressing leukemia subgroup.
The direct targeting of aberrant transcription factors as a therapeutic strategy remains a substantial challenge in cancer therapy. An alternative approach is to target the unique liabilities engendered by the altered cellular circuitry present in these transcription-factordriven malignancies. To this end, we have integrated 'omic' approaches to identify CKMT1 as a druggable liability in EVI-positive AML. In considering the clinical translation of this finding, it is notable that cyclocreatine can be found in marketed nutritional and sports supplements. In addition, although not specifically for the mechanism of CKMT1 inhibition but rather for use as a cell permeable analog of creatine, cyclocreatine was granted orphan drug designation by the European Commission to Pharma Gateway AB, Sweden, in 2016 for the treatment of syndromes involving creatine deficiencies. Despite enthusiasm about the likely safety of this molecule for multiple disease indications, clinical trials testing the safety and efficacy of cyclocreatine, however, will still need to be conducted. Another path forward for targeting CKMT1 might be the development of new selective agents that target this enzyme. In summary, our study supports a potential therapeutic avenue for targeting the creatine kinase pathway in EVI1-positive AML, which remains one of the worst outcome subtypes of this disease.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. value at the control condition. No or small variations in metabolite production as compared to the average value under control conditions appears closest to the white color on the heat map. Decreased or increased metabolite production relative to the average for the control condition is represented by a gradient of color from blue to red respectively. The MetaboAnalyst software (http://www. metaboanalyst.ca) was used to perform pathway-enrichment analysis on the set of top metabolite hits identified by steady-state profiling. No specific manual settings were needed to analyze the list of metabolites.
Chromatin immunoprecipitation and sequencing (ChIP-seq) and chromatin immunoprecipitation and sequencing (ChIP-qPCR). A gene track for Runx1 generated by ChIP-seq for the analysis of mouse-Evi1-binding peaks was obtained from A.S. Perkins (University of Rochester Medical Center, New York, NY, USA). The gene track for human RUNX1 was obtained from publicly available ChIP-seq data generated by Bard-Chapeau et al. 19 . The conservation score between species was computed based on phasCons data for the hg18 (human) and mm9 (mouse) genome sequences 41 . Gene tracks and EVI1-binding peaks were aligned using IGV software 42 .
ChIP-qPCR was performed as described by Bernt et al. 43 . Briefly, crosslinking was performed in cell culture medium containing 1% formaldehyde with gentle rotation for 5 min at room temperature. Fixation was stopped by the addition of glycine (125 mM final concentration). Fixed cells were washed twice in ice-cold PBS and then resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, supplemented with Complete mini protease inhibitor cocktail (Roche)). Chromatin was sheared to approximately 200-bp fragments by Covaris ultrasonication and immunoprecipitated. Precipitates were washed sequentially with ice-cold low-salt wash (0.1% SDS, 1% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1 and 150 mM NaCl), high-salt wash (0.1% SDS, 1% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1 and 500 mM NaCl), LiCl wash (0.25 M LiCl, 1% IGEPAL CA-630, 1% deoxycholic acid, 1 mM EDTA and 10 mM Tris-HCl, pH 8.1) and TE wash (1 mM EDTA and 10 mM TrisHCl, pH 8.1) and were eluted in elution buffer (1% SDS and 0.1M NaHCO 3 ). Eluted DNA fragments were analyzed by qPCR. Primers used for ChIP-qPCR are listed in Supplementary Table 7. Western immunoblotting. Western immunoblotting was performed as described previously 44 from cell lysates after normalization for total protein content. Lysates were boiled in Laemmli sample buffer and run on SDS-PAGE (PAGE) before transfer to nitrocellulose membranes and immunoblotting. A list of antibodies used for western immunoblotting is listed in Supplementary Table 8. Flow cytometry. Cell lines were washed in 0.1% BSA and 2 mM EDTA in PBS before a 45-min incubation with an human-CD117-specific antibody. Cells were then washed twice with PBS containing 0.1% BSA and 2 mM EDTA before analysis with a BC FACScanto II (BD Biosciences).
Primary cells from patients with AML were washed in PBS containing 0.1% BSA and 2 mM EDTA before a 45-min incubation with a combination of phycoerythrin (PE)-and Cy7-conjugated anti-human-CD13 and anti-human-CD33 (used at 1/50) or PE-and Cy7-conjugated isotype control antibodies. Cells were then washed twice with 0.1% BSA and 2 mM EDTA in PBS before a 20-min fixation with BD Cytofix/CytoPerm Fixation and Permeabilization Solution (BD Biosciences). Cells were then washed three times with BD Perm/Wash Buffer and incubated for 45 min at 4 °C with a nonconjugated anti-human-EVI1 (used at 1/50) or the corresponding isotype control antibody. Cells were washed three times with Perm/Wash Buffer and were incubated for 35 min with an AlexaFluor-488-conjugated goat anti-rabbit-IgG used at 1/500 (Invitrogen). Cells were washed three times in Perm/Wash Buffer and analyzed using a BD FACSCanto II analyzer. To account for any background fluorescence, the mean fluorescence level of EVI1 was normalized to the mean fluorescence level of its corresponding isotype control. This normalized value was then scaled for each patient using the z-score calculation across all patient samples.
Mouse bone marrow and spleen were collected from each organ, washed with PBS containing 0.1% BSA and 2 mM EDTA, and lysed for 10 min with red blood cell lysis buffer (Sigma). After two washing steps with PBS containing 0.1% BSA and 2 mM EDTA, bone marrow cells were stained for 30 min at 4 °C with a combination of lineage-marker-specific (Sca-1, c-kit, CD16, CD32 and CD34) antibodies, and spleen cells were incubated for 5 min at 4 °C with mouse BD Fc Block (BD Biosciences) before staining with the combination of Mac-1-and Gr-1-specific antibodies. Stained cell subpopulations were analyzed with a BD LSR-II analyzer (BD Biosciences).
A list of antibodies used for western immunoblotting and flow cytometry is listed in Supplementary Table 8. Genome-wide expression analysis. Genome profiling of Evi1-overexpressing mouse progenitor cells. GFP-positive control and Evi1-overexpressing progenitor cells were sorted, and total RNA was extracted and profiled using the GeneChip Mouse Gene 1.0 ST Array from Affymetrix (GSE39103) 16 .
Comparative marker and GSEA analyses. The six samples in the GSE39103 data available from the Gene Expression Omnibus (GEO) repository (http:// www.ncbi.nlm.nih.gov/geo/) were separated into two groups: control versus Evi1-overexpressing samples. The Comparative Marker Selection module from GenePattern v3.9.3 (ref. 45 ) was used to identify individual genes that were differentially expressed between the two groups. A permutation P ≤ 0.05, a Benjamini-Hochberg false discovery rate (FDR) ≤ 0.05 to account for multiple-hypothesis testing, and an absolute fold change ≥ 2 served as cutoff for significant expression of genes. The gene set enrichment analysis (GSEA) v.2.1.0 software 46, 47 was used to identify pathways or groups of functionally related genes that are deregulated by Evi1 overexpression. The goal of GSEA is to identify groups of genes that share common biologic function (gene sets), which are distributed at the top or bottom of the ranked list of differentially expressed genes. The significance of the enrichment score is estimated on the basis of a permutation P value and adjusted for multiple-hypothesis testing through the FDR. The set of differentially expressed genes that account for the enrichment signal is called the leading edge. GSEA was run on the c2 collection of 4,725 curated gene sets from MSigDB v.5.0 (http://software.broadinstitute.org/gsea/msigdb/). Gene sets with less than 15 genes or more than 500 genes were excluded from the analysis. Gene sets with a nominal P value ≤ 0.05 and FDR ≤ 0.25 were considered significant. The gene-ranking metric in the weighted enrichment score was the two-sided SNR, and the P values were calculated using 1,000 permutations of the phenotype.
Metabolic network. Each metabolic gene whose expression was deregulated after Evi1 overexpression was assigned to a functional group based on the c2 collection from MSigDB (http://www.genomespace.org). The enrichment results were visualized with the Enrichment Map module 48, 49 , which organizes the significant gene sets into a network called an 'enrichment map' . In the enrichment map, the nodes correspond to gene sets and the edges reflect significant overlap between the nodes according to a two-tailed Fisher exact test. The hubs correspond to collections of gene sets with a unifying class label according to gene ontology (GO) biologic processes. The size of the nodes is correlated with the number of genes in the gene set.
Gene expression profiling after cyclocreatine treatment. TF-1, UT-7 and UCSD-AML1 cells were treated in quadruplicate with either vehicle or 3 mM cyclocreatine for 24 h. Total RNA was extracted and profiled by RNA sequencing (HiSeq, Illumina) at the BioMicroCenter, Massachusetts Institute of Technology (Cambridge, MA, USA). The total number of reads for individual samples ranged from 44 to 48 Mb. Quality-control tests for the unmapped reads were performed using the FASTQC software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were aligned to the GRCh37 (hg19) GENCODE v.17 annotated human reference genome by using TopHat2 (ref. 50) . FPKM scores for genes were computed based on the RSEM R software package 51 . Expression data was evaluated as log 2 (FPKM). The significance of the differential expression between the control and cyclocreatine-treatment phenotypes was estimated using the EBSeq method implemented in R (Bioconductor v.3.3) 52 , based on the significance cutoff of 0.05 for the posterior probability. The aligned RNA-seq data is available at the GEO repository (GSE86151).
Comparative marker analysis. The 24 samples available in the RNA-seq data were separated into two groups: vehicle-treated (n = 12) and cyclocreatinetreated (n = 12). The Comparative Marker Selection module from GenePattern v.3.9.3 (ref. 45 ) was used to identify individual genes that were differentially expressed between the two conditions. The analysis was performed by applying a two-sided signal-to-noise ratio (SNR) test followed by 1,000 permutations of phenotype labels. The settings for the SNR parameters were: 'log-transformeddata' = no, 'complete' = no, 'balanced' = no, and 'smooth p values' = yes.
A 'core' cyclocreatine signature that consisted of 54 upregulated and 53 downregulated genes for cyclocreatine-treated samples relative to the vehicletreated samples was defined based on the cut-off SNR permutation iP ≤ 0.05, a Benjamini-Hochberg FDR ≤ 0.05 and an absolute fold change for log 2 (FPKM) scores ≥ 1.5. In addition, a 'relaxed' cyclocreatine signature consisting of 366 upregulated and 474 downregulated genes between the two conditions was defined based on the cut-off SNR permutation P ≤ 0.05, Benjamini-Hochberg FDR ≤ 0.05 and an absolute fold change for log 2 (FPKM) scores ≥ 0.5. The 'core' cyclocreatine signature is presented in Supplementary Tables 3 and 4 .
Gene set enrichment analysis (GSEA) and scatter plot. The GSEA v2.1.0 software 46, 47 was used to identify functional associations of the molecular phenotypes induced by cyclocreatine treatment with a compendia of gene signatures including the MSigDB v5.0 (refs. 47,53) c2 collection of 4,725 curated gene sets and c6 collection of 189 oncogenic signatures, the DMAP collection of hematopoietic lineage-differentiation signatures 53 and four AML differentiation gene signatures available from Gene Expression Omnibus (GEO) database (vitamin D-and phorbol 12-myristate 13-acetate (PMA)-induced differentiation signatures (accession number GSE995) 54 , JQ1-induced differentiation signature (accession number GSE29799) 55 and DOT1L-inhibitor-induced differentiation signature (accession number GSE29828) 56 ). Gene sets with less than 15 genes or with more than 500 genes were excluded from the analysis. Gene sets with an FDR ≤ 0.25 and a nominal P ≤ 0.05 were considered significant hits. The results were plotted on volcano plots and visualized on a functional network called an enrichment map. In the enrichment map, the nodes correspond to gene sets, and the edges reflect significant overlap between the nodes according to a two-tailed Fisher exact test. The size of the nodes is correlated with the gene set enrichment significance (−log 10 (P value)). The hubs correspond to collections of gene sets with a unifying functional category label.
In silico tests for high versus low CKMT1 expression in primary samples from subjects with AML. The in silico test used to determine the proportion of patients with EVI1 high RUNX1 low , EVI1 high RUNX1 high , EVI1 low RUNX1 low and EVI1 low RUNX1 high expression and who had high CKMT1 versus low CKMT1 expression levels was carried out on the Affymetrix U133 Plus2 gene expression data GSE14468 (ref. 57) (526 AML samples) and GSE10358 (ref. 58) (279 AML samples). Data were downloaded from the InSilico DB Genomic Data Sets Hub (http://www.genomespace.org). EVI1, RUNX1 and CKMT1 expression levels were computed for each sample in these two cohorts and were further transformed into a z-score by subtracting the average of the EVI1, RUNX1 and CKMT1 expression levels assigned to all other samples and by dividing the result to their s.d. For each patient, high versus low expression levels of EVI1, RUNX1 and CKMT1 were evaluated based on the absolute cut-off of a z-score (z-score ≥ 0.58 was considered to be high expression, and a z-score ≤ −0.58 was considered to be low expression). The significance of the differences between the proportions of patients with high and low CKMT1 expression within patient subgroups with high and low expression levels of EVI1 and RUNX1 was estimated by applying the two-tailed Fisher's exact test implemented in the function 'fisher.test' (library stats, R 3.2; http://cran.r-project.org/). Additional methods are available in the Supplementary Note. Data availability. Data for various analyses have been mentioned throughout the text and are available under accession codes GSE39103, GSE86151, GSE995, GSE29799, GSE29828, GSE14468 and GSE10358. Any other data associated with this study are available in the supplementary information. Additional methods are available in the Supplementary Note.
